Table 1.

Patient Characteristics and Delivery of Therapy (n = 102)

Characteristic	Patients
	No.	%
Age, years
Median	61
Range	23-82
Male	75	74
Rai stage
0	1	1
I-II	71	69
III-IV	30	30
FR induction
No. of cycles completed
≥ 3	95	93
6	79	77
Alemtuzumab consolidation (n = 58)
No. of weeks completed
≥ 3	53	91
6	42	72

Abbreviation: FR, fludarabine plus rituximab.